1Cannon CP.Overcoming thrombolytic resistance: Rationale and initial clinical experience Combining thrombolytic therapy and glycoprotein Ⅱ b Ⅲ a receptor inhibition for acute myocardial infarction[].Journal of the American College of Cardiology.1999
2Savicic M,Hanert J,Bachmann F,et al.Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy Subjects[].Seminars in Thrombosis and Hemostasis.1999
3Cannon CP,Dingemanse J,Kleinbloesem CH,et al.An automated heparin titration device to control activated partial thromboplastin time: Evaluation in normal volunteers[].Circulation.1999
4Loh E,Sutton MS,Wun CC,et al.Ventricular dysfunction and the risk of stroke after myocardial Infarction[].The New England Journal of Medicine.1997
5Steinhubl SR,Tan WA,Foody JM,et al.Incidence and Clinical Course of thrombotic thrombocytopenic purpura due to ticlopidine of following Coronary Stenting.EPISTENT Investigators:Evaluation of platelet Ⅱb Ⅲa Inhibition for stenting[].The Journal of The American Medical Association.1999
6Becker RC,Cannon CP,Tracy RP,et al.Relationship between Systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in hospital Clinical events in unstable angina and non-Q wave myocardial infarction[].American Heart Journal.1996
7Clinical Collaborative Study Group of Low Molecular Weight Heparin (Correspondent: HU Dayi, XU Juntang. Beijing Red Cross Chaoyang Hospital, Beijing University of Medical Sciences, Beijing 100020, China).不稳定性心绞痛、急性非Q波心肌梗死不同抗栓疗法的对比研究[J].中华心血管病杂志,2000,28(1):18-21. 被引量：172
